Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study.
Ji MaRuya LiFang XuFang ZhuXiangwei XuPublished in: Evidence-based complementary and alternative medicine : eCAM (2023)
Overall, this study illustrates the anti-NAFLD mechanism of dehydrovomifoliol, which could be a useful compound for developing novel drugs in the treatment of NAFLD.